目的 探讨UGTs、ABCC2、SLCO1B1和IMPDH基因多态性与肾移植术后早期受者霉酚酸酯代谢和不良反应的相关性。方法 共纳入233 例活体肾移植术后采用他克莫司+糖皮质激素+霉酚酸酯三联治疗方案的患者,采用基质辅助激光解吸电离飞行时间质谱方法检测13个基因位点的单核苷酸多态性,用Kruskal-Wallis H检验分析13个单核苷酸多态性对肾移植术后早期受者霉酚酸的体内暴露量/剂量(AUC/D)及不良反应的影响。结果 UGT2B7 802C>T CC和CT基因型受者霉酚酸的AUC/D分别为(36.03±16.19)和(38.06±15.41) mg·h·L-1/g·d-1,显著低于TT基因型受者的(43.63±15.10)mg·h·L-1/g·d-1(P=0.021)。SLCO1B1 521T>C TT、TC和CC基因型受者MPA的AUC/D分别为(36.78±15.70)、(41.27±12.92)和(45.10±21.32) mg·h·L-1/g·d-1,组间有显著性差异(P=0.036)。13个单核苷酸多态性与不良反应间差异无统计学意义(P>0.05)。结论 肾移植术后早期受者霉酚酸的AUC/D与UGT2B7 802C>T和SLCO1B1 521T>C基因多态性相关。
Abstract
OBJECTIVE To investigate the association of UGTs, ABCC2, SLCO1B1 and IMPDH gene polymorphisms with metabolism and adverse reaction of mycophenolate ester in early renal transplant recipients. METHODS A total of 233 patients who received tacrolimus+glucocorticoid+mycophenolate mofetil treatment after living kidney transplantation were enrolled. Single nucleotide polymorphisms of 13 gene were detected by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Kruskal-Wallis H test was used to analyze the effect of 13 single nucleotide polymorphisms on the exposure/dose (AUC/D) and adverse reactions of mycophenolic acid in early recipients after renal transplantation. RESULTS The AUC/D of mycophenolic acid in UGT2B7 802C>T CC and CT genotype recipients was (36.03±16.19) and (38.06±15.41) mg·h·L-1/g·d-1, which was significantly lower than that in TT genotype recipients (43.63±15.10) mg·h·L-1/g·d-1 (P=0.021). The AUC/D of mycophenolic acid in SLCO1B1 521T > C TT, TC and CC genotype recipients were (36.78±15.70), (41.27±12.92) and (45.10±21.32) mg·h·L-1/g·d-1, respectively. There was significant difference between groups (P=0.036). There was no significant difference between 13 single nucleotide polymorphisms and adverse reactions (P>0.05). CONCLUSION The AUC/D of mycophenolic acid in early recipients after kidney transplantation are associated with the polymorphism of UGT2B7 802C > T and SLCO1B1 521T > C.
关键词
霉酚酸酯 /
基因多态性 /
肾移植术后早期受者 /
代谢 /
不良反应
{{custom_keyword}} /
Key words
mycophenolate mofetil /
gene polymorphism /
early recipients after kidney transplantation /
metabolism /
adverse reaction
{{custom_keyword}} /
中图分类号：
R969.3
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] YANG J, LU J L, ZHANG A L, et al. Advances in gene polymorphisms related to mycophenolic acid pharmacokinetics and pharmacodynamics[J]. Chin J Clin Pharm (中国临床药学杂志), 2016,25(5):324-328.
[2] MILES K K, STERN S T, SMITH P C, et al. An investigation of human and rat liver microsomal mycophenolic acid glucuronidation: evidence for a principal role of UGT1A enzymes and species differences in UGT1A specificity[J]. Drug Metab Dispos, 2005, 33(10):1513-1520.
[3] TETT S E, SAINT-MARCOUX F, STAATZ C E, et al. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure[J]. Transplant Rev, 2011, 25(2):47-57.
[4] EVANS W E, MCLEOD H L. Pharmacogenomics-drug disposition, drug targets, and side effects[J]. New Engl J Med, 2003, 348(6):538-549.
[5] GENG F, JIAO Z, DAO Y J, et al. The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals[J]. Clin Chim Acta, 2012, 413(7-8):683-690.
[6] WOILLARD J B, PICARD N, THIERRY A, et al. Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients[J]. Pharmacogenet Genom, 2014, 24(5):256-262.
[7] GRINYÓ J, VANRENTERGHEM Y, NASHAN B, et al. Association of four DNA polymorphisms with acute rejection after kidney transplantation[J]. Transplant Int, 2008, 21(9):879-891.
[8] FILLER G. Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy[J]. Transplant Int, 2004, 17(3):120-125.
[9] CHEN S Y, CAI J X, ZHANG W P, et al. Proteomic analysis of proteins associated with the paclitaxel-induced drug-resistant human breast cancer cells [J]. Chin Pharm J (中国药学杂志), 2014, 49(10):825-832.
[10] ZHOU P J, XU D, YU Z C, et al. Pharmacokinetics of mycophenolic acid and estimation of exposure using multiple linear regression equations in Chinese renal allograft recipients[J]. Clin Pharmacokinet, 2007, 46(5):389-401.
[11] KUYPERS D R J, NAESENS M, VERMEIRE S, et al. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients[J]. Clin Pharmacol Ther, 2005, 78(4):351-361.
[12] SÁNCHEZ-FRUCTUSOS A I, MAESTRO M L, CALVO N, et al. The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients[J]. Transpl P, 2009, 41(6):2313-2316.
[13] TING L S L, BENOIT-BIANCAMANO M, BERNARD O, et al. Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study[J]. Pharmacotherapy, 2010, 30(11):1097-1108.
[14] SHIPKOVA M, SCHUTZ E, ARMSTRONG V W, et al. Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite[J]. Transpl P,1999, 31(1-2):1135-1137.
[15] PITHUKPAKORN M, TIWAWANWONG T, LALERD Y, et al. Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms[J]. Pharmacogen Pers Med, 2014, 7: 379-385.
[16] PICARD N, YEE S W, WOILLARD J B, et al. The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics[J]. Clin Pharmacol Ther, 2010, 87(1):100-108.
[17] MIURA M, SATOH S, INOUE K, et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients[J]. Eur J Clin Pharmacol, 2007, 63(12):1161-1169.
[18] EL-SHEIKH A A K, KOENDERINK J B, WOUTERSE A C, et al. Renal glucuronidation and multidrug resistance protein 2-/multidrug resistance protein 4-mediated efflux of mycophenolic acid: interaction with cyclosporine and tacrolimus[J]. Transl Res, 2014, 164(1):46-56.
[19] CATTANEO D, PERICO N, GASPARI F, et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation[J]. Kidney Int, 2002, 62(3):1060-1067.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
河南省医学科技攻关项目资助(182102310146)
{{custom_fund}}
PDF(3634 KB)
